




STRATEGIC PLAN



- 3D-QSAR (Quantum Structure-Activity Relationship) Models
 - Molecular docking
 - Molecular dynamics
 - Quantum mechanical methods
 - Molecular mechanical methods
 - Pharmacophore modelling
-
- 3D cell metabolism studies
 - Live cell studies
 - CYPs inhibition studies
 - CYPs induction studies
 - Protein binding studies
 - RBC partitioning studies
 - Permeability studies
 - NERG studies
 - Mechanistic toxicity/ cytotoxicity studies
-
- DMPK (Drug Metabolism Pharmacokinetics) studies
 - Toxicokinetic studies





- define the patient group that will gain benefit
- define the druggable key-players (proteins, proteoforms, protein variants)
- select repurposed drugs based on AI & human synergies
- profile candidates (efficacy, ADMETox)
- identify & validate companion biomarkers



- proteomics-based multi-omics
- artificial-human intelligence workspace -> data mining and curation -> data reliability & reproducibility
- validation; spatial proteomics, single cell and/or exosomal proteomics, photoacoustic-LC-MSn.



- genotype-to-phenotype associations -> clinical interpretome
- monitoring of immunomodulatory mechanisms
- ADMETox profiling for cell- & gene- therapies



- consumer-generated physiological measures
- consumer-generated behavioral measures
- digital tools



- family health history profiling
- companion biomarkers
- point-of-care testing